HMGCR

3-hydroxy-3-methylglutaryl-coenzyme A reductase · P04035 · HMGCR on Sugi Atlas →

46,471 patent compounds predicted against HMGCR, 30,006 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Glenvastatin (SCHEMBL49508)	1.00	12/20
Tenivastatin (SCHEMBL110804)	0.84	11/20
SCHEMBL245091	0.74	11/20
SCHEMBL245092	0.74	11/20
Pravastatin (SCHEMBL3013)	1.00	10/20
Pravastatin (SCHEMBL3014)	1.00	10/20
Atorvastatin (SCHEMBL3831)	1.00	10/20
Atorvastatin (SCHEMBL28457)	0.98	10/20
Atorvastatin (SCHEMBL149164)	0.98	10/20
Atorvastatin (SCHEMBL336684)	0.98	10/20
Atorvastatin (SCHEMBL346513)	0.98	10/20
Pravastatin (SCHEMBL25969)	0.97	10/20
Atorvastatin (SCHEMBL34266)	0.97	10/20
Pravastatin (SCHEMBL344523)	0.79	10/20
SCHEMBL247233	0.74	10/20
SCHEMBL247234	0.74	10/20
Pravastatin (SCHEMBL367687)	0.70	10/20
SCHEMBL246624	0.55	10/20
SCHEMBL246625	0.55	10/20
Pravastatin (SCHEMBL1117)	1.00	9/20

Clinical trials — most relevant to HMGCR by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Living With Statins - The Impact of Cholesterol Lowering Drugs on Health, Lifestyle and Well-being	PHASE4	COMPLETED
Comparison of Low-Intensity Statin Plus Ezetimibe Versus High-Intensity Statin Therapy on Risk of New-Onset Diabetes Mellitus (PROVE-DM)	PHASE4	ENROLLING_BY_INVITATION
Long Term Efficacy and Tolerability of a Nutraceutical Combination (Red Yeast Rice, Policosanols and Berberine) in Low-moderate Risk Hypercholesterolemic Patients: a Double-blind, Placebo Controlled Study	PHASE4	COMPLETED
Carotid Atherosclerosis Regression at Magnetic Resonance Assessment.	PHASE4	COMPLETED
Living With Statins - Interventional Exercise Study	PHASE4	UNKNOWN
Relationship Between Insulin Resistance and Statin Induced Type 2 Diabetes, and Integrative Personal Omics Profiling	PHASE4	COMPLETED
A Study Comparing the Mechanisms of Action of Lifibrol and Pravastatin	PHASE3	COMPLETED
Comparison of Coenzyme A and Pantethine Capsule for Safety and Efficacy On Patients With Hyperlipidemia	PHASE3	COMPLETED
Phospholipovit vs Placebo in Patients With Combined Hyperlipidemia	PHASE2/PHASE3	COMPLETED
Effect of Vitamin D Supplementation on Exercise Adaptations in Patients on Statin Therapy	PHASE3	COMPLETED
PCSK 9 Inhibition as Secondary Prevention in Renal Transplant Patients	PHASE3	COMPLETED
Efficacy of Lapaquistat Acetate Alone or Combined With Simvastatin in Subjects With Hypercholesterolemia	PHASE3	COMPLETED
Simvastatin Effect in Combination With Neoadjuvant Chemotherapy to Clinical Response and Tumor-Free Margin in Locally Advanced Breast Cancer	PHASE2	COMPLETED
Atorvastatin Effects On Arterial Stiffness In Hemodialysis	PHASE2	COMPLETED
Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer	PHASE2	COMPLETED
Phase 2 Study of Atorvastatin Safety and Antitumor Effects in Non-Hodgkin's Lymphoma	PHASE2	COMPLETED
Cholesterol Reduction in Seniors Program (CRISP)	PHASE2	COMPLETED
Phase II Study of Simvastatin Plus Irinotecan, Fluorouracil, and Leucovorin(FOLFIRI) for Metastatic CRC	PHASE2	COMPLETED
Clinical Effects of New Approach on Patients With Non-alcoholic Steatohepatitis	EARLY_PHASE1	COMPLETED
Cellular Effect of Cholesterol-Lowering Prior to Prostate Removal	EARLY_PHASE1	COMPLETED
Influence of Simvastatin on Apolipoprotein B-100 (apoB-100) Secretion	nan	COMPLETED
Ekvasis of Atorvastatin (Antorcin®) Treatment in Patients With Acute Cardiovascular Events	nan	COMPLETED
Atorvastatin Versus Ezetimibe and Fenofibrate as a Lipid-lowering Strategy	nan	COMPLETED
LIFESTAT - Living With Statins, a Cross Sectional Study	nan	COMPLETED
Effect of Statin Preloading in STEMI in Improving PCI Outcomes	nan	UNKNOWN
STATIC - Statin Termination in Cancer	nan	RECRUITING
Effect of Atorvastatin on 5-Fluorouracil Induced Mucositis	nan	UNKNOWN
Effects of Usage of Simvastatin in Mild to Moderate Traumatic Brain Injury (TBI) Patients. Could it Make a Difference?	nan	UNKNOWN
Genetically Guided Statin Therapy	nan	COMPLETED
Pravastatin Therapy in Patients With Active Crohn's Disease: A Pilot Study	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a HMGCR binder may also engage these)

Protein	Name	Similarity
Q1W675	—	1.000	Q1W675 →
Q5R6N3	—	1.000	Q5R6N3 →
Q29512	—	1.000	Q29512 →
A7Z064	—	1.000	A7Z064 →
P00347	—	1.000	P00347 →
Q01237	—	1.000	Q01237 →
P09610	—	1.000	P09610 →
P51639	—	1.000	P51639 →
Q41437	—	1.000	Q41437 →
P54960	—	1.000	P54960 →
P48020	—	1.000	P48020 →
P20715	—	1.000	P20715 →
Q03163	—	1.000	Q03163 →
Q01559	—	0.998	Q01559 →
O64966	—	0.997	O64966 →
P29057	—	0.997	P29057 →
Q41438	—	0.997	Q41438 →
P12683	—	0.997	P12683 →
U5JCC6	—	0.997	U5JCC6 →
O64967	—	0.996	O64967 →
P16393	—	0.996	P16393 →
Q9XEL8	—	0.995	Q9XEL8 →
O74164	—	0.994	O74164 →
P14773	—	0.994	P14773 →
Q4WSY2	—	0.994	Q4WSY2 →
A0A803NI27	—	0.994	A0A803NI27 →
B9IJ21	—	0.993	B9IJ21 →
A0A0A1C930	—	0.993	A0A0A1C930 →
A0A7J6H013	—	0.993	A0A7J6H013 →
P48022	—	0.991	P48022 →